

Special Issue

Endocrine Autoimmune Diseases: Pathogenesis and Personalized Therapy

Message from the Guest Editors

The investigation of autoimmune endocrine diseases is proving to be of crucial importance for early diagnosis and prompt management. Notably, if the management is delayed or not tailored, it can even be fatal.

Personalized therapy could be the answer to the challenge in therapy of endocrine autoimmune disorders and endocrine immunotherapy toxicity. According to the clinical, histological and molecular characteristics, the therapy can be tailored to the patient in order to obtain the maximum efficacy of the treatment and of the patient's compliance. The prompt diagnosis of endocrine toxicity in cancer patients in immunotherapy is also an important factor and a great determinant to adherence to immunotherapy. The Special Issue, entitled 'Autoimmune Diseases: Pathogenesis and Personalized Therapy', invites research and papers concerning the autoimmune endocrine diseases and endocrine adverse events related to immunotherapy, their diagnosis, and their treatment. Authors are invited to participate with clinical research articles, reviews, and communications.

Guest Editors

Dr. Sabrina Chiloiri


Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

Dr. Emilia Sbardella

Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy

Deadline for manuscript submissions

closed (30 September 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/139035

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).